Markets

Achillion Pharmaceuticals (ACHN) in Focus: Stock Rises 47.6% - Tale of the Tape

Achillion Pharmaceuticals, Inc. ( ACHN ) was a big mover last session, as its shares rose nearly 48% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent near-flat trend for the company, as the stock is now trading above the volatile price range of $2.67 to $2.95 in the past one-month timeframe.

In the last 30 days, the company witnessed one negative estimate revision while the Zacks Consensus Estimate remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Achillion Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Other better-ranked stocks in the medical sector include Gilead Sciences Inc. ( GILD ), ANI Pharmaceuticals, Inc. ( ANIP ) and Illumina Inc. ( ILMN ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More